Citations

Clear

95 citation(s) found for "Diamond, M P".

Apparent Behavioral Benefits of Tau Overexpression in P301L Tau Transgenic Mice
Morgan, Dave, Munireddy, Sanjay, Alamed, Jennifer, DeLeon, Jason, Diamond, David M. , Hutton, Michael , Lewis, Jada , Gordon, Marcia N. , Bickford, Paula C. , McGowan, Eileen

Mayo Clinic

Journal of Alzheimer's Disease | April 5, 2017 | Volume: 15 | Issue: 4 | Pages: 605-614

10.3233/jad-2008-15407 | PMID 19096159 Get It

What Are the Indications for Spinal Fusion Surgery in Scheuermann Kyphosis?
Polly, David W. , Ledonio, Charles Gerald T., Diamond, Beverly, Labelle, Hubert , Sucato, Daniel J. , Hresko, M. Timothy , Emans, John B. , Vitale, Michael G. , Erickson, Mark A. , Larson, A. Noelle , Polly, David

Mayo Clinic

Journal of Pediatric Orthopaedics | February 11, 2017 | Volume: 39 | Issue: 5 | Pages: 217-221

10.1097/bpo.0000000000000931 | PMID 30969249 Get It

Background: Surgical indications for Scheuermann kyphosis are variable. We sought to evaluate the characteristics of patients undergoing operative versus nonoperative treatment of Scheuermann kyphosis to better understand current practices and the factors which contribute to the decision for surgical management. Methods: Multicenter prospective cohort study. We evaluated consecutive patients presenting with Scheuermann kyphosis. Patients underwent either surgical or nonoperative management according to surgeon and patient discretion. Preoperative patient-reported outcome measures (Scoliosis Research Society and Spinal Appearance Questionnaire scores), demographics, and radiographic characteristics were assessed. Results: Overall, 150 patients with Scheuermann kyphosis were enrolled, with 77 choosing nonoperative treatment and 73 treated operatively. Compared with the nonoperative cohort, patients treated operatively were older (16.3±2.0 vs. 15.1±2.2, P=0.0004), and had higher body mass index (26.3±7.2 vs. 22.7±6.5, P=0.003), had greater T2-T12 kyphosis (71±14 degrees vs. 61±12 degrees, P<0.001), increased pelvic incidence (46 vs. 41 degrees, P=0.03) and pelvic tilt (10 vs. 3 degrees, P=0.03). There was no detected difference in maximal sagittal Cobb angle in the operative versus nonoperative patients (73±11 vs. 70±12 degrees, P=0.11). Functionally, the operative patients had worse Scoliosis Research Society pain scores (3.7±0.9 vs. 4.1±0.7, P=0.0027) and appearance scores (2.9±0.7 vs. 3.4±0.8, P <0.0001). Conclusions: Patients undergoing surgical management of Scheuermann disease were more likely to have large body mass index and worse pain scores. Other factors beyond radiographic measurement likely contribute to the decision for surgical management of Scheuermann kyphosis. Level of Evidence: Level II.
Amending HIV Drugs: A Novel Small-Molecule Approach To Target Lupus Anti-DNA Antibodies
VanPatten, Sonya , Sun, Shan , He, Mingzhu , Altiti, Ahmad S. , Papatheodorou, Angelos, Kowal, Czeslawa, Jeganathan, Venkatesh, Crawford, James M. , Bloom, Ona , Grant, Christian , Meurice, Nathalie , Coleman, Thomas R., Diamond, Betty , Al‐Abed, Yousef , Cheng, Kai Fan , Volpe, Bruce T.

Mayo Clinic

Journal of Medicinal Chemistry | September 7, 2016 | Volume: 59 | Issue: 19 | Pages: 8859-8867

10.1021/acs.jmedchem.6b00694 | PMID 27603688 Get It

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
Emile, Jean‐François , Abla, Oussama , Fraitag, Sylvie , Horne, AnnaCarin , Haroche, Julien , Requena‐Caballero, Luis, Jordan, Michael B. , Allen, Carl E. , Charlotte, Frédéric , Egeler, R. Maarten , Herrera, Juana Gil, Henter, Jan‐Inge , Jankú, Filip , Mérad, Miriam , Rollins, Barret J., Tazi, Abdellatif , Vassallo, Robert , Weiss, Lawrence M. , Astigarraga, Itziar , Donadieu, Jean , Abdel‐Wahab, Omar , Diamond, Eli L. , Fischer, Alain , Picarsic, Jennifer , Rodríguez‐Galindo, Carlos , Vassallo, Robert , Emile, Jean-François , Allen, Carl E

Mayo Clinic

Blood | March 10, 2016 | Volume: 127 | Issue: 22 | Pages: 2672-2681

10.1182/blood-2016-01-690636 | PMID 26966089 Get It

Abstract The histiocytoses are rare disorders characterized by the accumulation of macrophage, dendritic cell, or monocyte-derived cells in various tissues and organs of children and adults. More than 100 different subtypes have been described, with a wide range of clinical manifestations, presentations, and histologies. Since the first classification in 1987, a number of new findings regarding the cellular origins, molecular pathology, and clinical features of histiocytic disorders have been identified. We propose herein a revision of the classification of histiocytoses based on histology, phenotype, molecular alterations, and clinical and imaging characteristics. This revised classification system consists of 5 groups of diseases: (1) Langerhans-related, (2) cutaneous and mucocutaneous, and (3) malignant histiocytoses as well as (4) Rosai-Dorfman disease and (5) hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Herein, we provide guidelines and recommendations for diagnoses of these disorders.
Phase I Study of DMOT4039A, an Antibody–Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Weekes, Colin D. , Lamberts, Laetitia E., Voortman, Johannes, Diamond, Jennifer R. , Vries, Elisabeth G.E. de , Verheul, Henk M.W. , Kim, George P., Wang, Yulei , Scales, Suzie J. , Samineni, Divya , Brunstein, Flávia, Choi, YounJeong, Maslyar, Daniel, Colón‐Otero, Gerardo , McWilliams, Robert R. , Borad, Mitesh J. , Lieu, Christopher H. , de Vries, Elisabeth G E

Mayo Clinic

Molecular Cancer Therapeutics | January 29, 2016 | Volume: 15 | Issue: 3 | Pages: 439-447

10.1158/1535-7163.mct-15-0693 | PMID 26823490 Get It

Abstract DMOT4039A, a humanized anti-mesothelin mAb conjugated to the antimitotic agent monomethyl auristatin E (MMAE), was given to patients with pancreatic and ovarian cancer every 3 weeks (0.2–2.8 mg/kg; q3w) or weekly (0.8–1.2 mg/kg). A 3+3 design was used for dose escalation followed by expansion at the recommended phase II dose (RP2D) to evaluate safety and pharmacokinetics. Antitumor response was evaluated per RECIST 1.1 and serum CA19-9 or CA125 declines. Tumor mesothelin expression was determined by IHC. Seventy-one patients (40 pancreatic cancer; 31 ovarian cancer) were treated with DMOT4039A. For the q3w schedule (n = 54), the MTD and RP2D was 2.4 mg/kg, with dose-limiting toxicities of grade 3 hyperglycemia and grade 3 hypophosphatemia at 2.8 mg/kg. For the weekly schedule (n = 17), the maximum assessed dose was 1.2 mg/kg, with further dose escalations deferred because of toxicities limiting scheduled retreatment in later cycles, and therefore the RP2D level for the weekly regimen was determined to be 1 mg/kg. Across both schedules, the most common toxicities were gastrointestinal and constitutional. Treatment-related serious adverse events occurred in 6 patients; 4 patients continued treatment following dose reductions. Drug exposure as measured by antibody-conjugated MMAE and total antibody was generally dose proportional over all dose levels on both schedules. A total of 6 patients had confirmed partial responses (4 ovarian; 2 pancreatic) with DMOT4039A at 2.4 to 2.8 mg/kg i.v. q3w. DMOT4039A administered at doses up to 2.4 mg/kg q3w and 1.0 mg/kg weekly has a tolerable safety profile and antitumor activity in both pancreatic and ovarian cancer. Mol Cancer Ther; 15(3); 439–47. ©2016 AACR.
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Diamond, Eli L. , Durham, Benjamin H. , Haroche, Julien , Yao, Zhan , Ma, Jing , Wang, Zhaoming , Choi, John , Kim, Eun Hee , Cohen‐Aubart, Fleur , Lee, Stanley Chun-Wei , Gao, Yijun , Micol, Jean‐Baptiste , Campbell, Patrick , Walsh, Michael P. , Sylvester, Brooke E., Dolgalev, Igor , Aminova, Olga, Heguy, Adriana , Zappile, Paul, Nakitandwe, Joy , Ganzel, Chezi , Dalton, James , Ellison, David W. , Estrada‐Veras, Juvianee , Lacouture, Mario E. , Gahl, William A. , Stephens, Philip J., Miller, Vincent A. , Ali, Siraj M. , Briggs, Samuel, Fasan, Omotayo , Block, Jared , Héritier, Sébastien , Solit, David B. , Hyman, David M. , Baselga, José , Jankú, Filip , Taylor, Barry S. , Amoura, Zahir , Rosen, Neal , Parikh, Sameer A. , Ross, Jeffrey S , Donadieu, Jean , Park, Christopher Y. , Doǧan, Ahmet , Emile, Jean‐François , Gruber, Tanja Andrea , Abdel‐Wahab, Omar , Diamond, Eli L , Wang, Zhaoming , Héritier, Sébastien , Durham, Benjamin

Mayo Clinic

Cancer Discovery | November 13, 2015 | Volume: 6 | Issue: 2 | Pages: 154-165

10.1158/2159-8290.cd-15-0913 | PMID 26566875 Get It

Abstract Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans cell histiocytosis (LCH) and non-Langerhans cell histiocytosis (non-LCH), respectively. The discovery of BRAFV600E mutations in approximately 50% of these patients provided the first molecular therapeutic target in histiocytosis. However, recurrent driving mutations in the majority of patients with BRAFV600E–wild-type non-LCH are unknown, and recurrent cooperating mutations in non-MAP kinase pathways are undefined for the histiocytic neoplasms. Through combined whole-exome and transcriptome sequencing, we identified recurrent kinase fusions involving BRAF, ALK, and NTRK1, as well as recurrent, activating MAP2K1 and ARAF mutations in patients with BRAFV600E–wild-type non-LCH. In addition to MAP kinase pathway lesions, recurrently altered genes involving diverse cellular pathways were identified. Treatment of patients with MAP2K1- and ARAF-mutated non-LCH using MEK and RAF inhibitors, respectively, resulted in clinical efficacy, demonstrating the importance of detecting and targeting diverse kinase alterations in these disorders. Significance: We provide the first description of kinase fusions in systemic histiocytic neoplasms and activating ARAF and MAP2K1 mutations in non-Langerhans histiocytic neoplasms. Refractory patients with MAP2K1- and ARAF-mutant histiocytoses had clinical responses to MEK inhibition and sorafenib, respectively, highlighting the importance of comprehensive genomic analysis of these disorders. Cancer Discov; 6(2); 154–65. ©2015 AACR. This article is highlighted in the In This Issue feature, p. 109
Raman Microscopic Analysis of Internal Stress in Boron-Doped Diamond
Bennet, Kevin E. , Lee, Kendall, Tomshine, Jonathan R. , Sundin, Emma , Kruchowski, James, Durrer, William, Manciu, Bianca, Kouzani, Abbas Z. , Manciu, Felicia , Lee, Kendall H. , Kouzani, Abbas Z , Manciu, Felicia S

Mayo Clinic

Materials | May 26, 2015 | Volume: 8 | Issue: 5 | Pages: 2782-2793

10.3390/ma8052782 Get It

Analysis of the induced stress on undoped and boron-doped diamond (BDD) thin films by confocal Raman microscopy is performed in this study to investigate its correlation with sample chemical composition and the substrate used during fabrication. Knowledge of this nature is very important to the issue of long-term stability of BDD coated neurosurgical electrodes that will be used in fast-scan cyclic voltammetry, as potential occurrence of film delaminations and dislocations during their surgical implantation can have unwanted consequences for the reliability of BDD-based biosensing electrodes. To achieve a more uniform deposition of the films on cylindrically-shaped tungsten rods, substrate rotation was employed in a custom-built chemical vapor deposition reactor. In addition to visibly preferential boron incorporation into the diamond lattice and columnar growth, the results also reveal a direct correlation between regions of pure diamond and enhanced stress. Definite stress release throughout entire film thicknesses was found in the current Raman mapping images for higher amounts of boron addition. There is also a possible contribution to the high values of compressive stress from sp2 type carbon impurities, besides that of the expected lattice mismatch between film and substrate.
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
Diamond, Eli L. , Dagna, Lorenzo , Hyman, David M. , Cavalli, Giulio , Jankú, Filip , Estrada‐Veras, Juvianee , Ferrarini, Marina , Abdel‐Wahab, Omar , Heaney, Mark , Feeley, Nancy , McClain, Kenneth L. , Vaglio, Augusto , Colby, Thomas V. , Arnaud, Laurent , Haroche, Julien , Colby, Thomas, Scheel, Paul J. , Ferrero, Elisabetta , Diamond, Eli L , Abdel-Wahab, Omar , McClain, Kenneth L , Vaglio, Augusto

Mayo Clinic

Blood | May 22, 2014 | Volume: 124 | Issue: 4 | Pages: 483-492

10.1182/blood-2014-03-561381 | PMID 24850756 Get It

Abstract Erdheim-Chester disease (ECD) is a rare, non-Langerhans histiocytosis. Recent findings suggest that ECD is a clonal disorder, marked by recurrent BRAFV600E mutations in >50% of patients, in which chronic uncontrolled inflammation is an important mediator of disease pathogenesis. Although ∼500 to 550 cases have been described in the literature to date, increased physician awareness has driven a dramatic increase in ECD diagnoses over the last decade. ECD frequently involves multiple organ systems and has historically lacked effective therapies. Given the protean clinical manifestations and the lack of a consensus-derived approach for the management of ECD, we provide here the first multidisciplinary consensus guidelines for the clinical management of ECD. These recommendations were outlined at the First International Medical Symposium for ECD, comprised of a comprehensive group of international academicians with expertise in the pathophysiology and therapy of ECD. Detailed recommendations on the initial clinical, laboratory, and radiographic assessment of ECD patients are presented in addition to treatment recommendations based on critical appraisal of the literature and clinical experience. These formalized consensus descriptions will hopefully facilitate ongoing and future research efforts in this disorder.
Development of Conductive Boron-Doped Diamond Electrode: A microscopic, Spectroscopic, and Voltammetric Study
Bennet, Kevin E. , Lee, Kendall, Kruchowski, James, Chang, Su-Youne , Marsh, Michael, Orsow, Alexander Van, Paez, Aurelio, Manciu, Felicia , Kruchowski, James N, Marsh, Michael P., Van Orsow, Alexander A, Lee, Kendall H. , Manciu, Felicia S

Mayo Clinic

Materials | December 6, 2013 | Volume: 6 | Issue: 12 | Pages: 5726-5741

10.3390/ma6125726 | PMID 28788420 Get It

Building on diamond characteristics such as hardness, chemical inertness and low electron emission threshold voltage, the current microscopic, spectroscopic and voltammetric investigations are directed towards improving the properties of electrode coating materials for their future use in clinical studies of deep brain stimulation via fast-scan cyclic voltammetry (FSCV). In this study we combine the capabilities of confocal Raman mapping in providing detailed and accurate analysis of local distributions of material constituents in a series of boron-doped polycrystalline diamond films grown by chemical vapor deposition, with information from the more conventional techniques of scanning electron microscopy (SEM) and infrared absorption spectroscopy. Although SEM images show a uniform distribution of film crystallites, they have the limitation of being unable to differentiate the distribution of boron in the diamond. Values of 1018–1021 atoms/cm3 of boron content have been estimated from the absorption coefficient of the 1290 cm−1 infrared absorption band and from the 500 cm−1 Raman vibration. The observed accumulation of boron atoms and carbon sp2 impurities at the grain boundaries suggests that very high doping levels do not necessarily contribute to improvement of the material’s conductivity, corroborating with voltammetric data. FSCV results also indicate an enhanced stability of analyte detection.
An examination of male‐female differences in progression and mortality of Parkinson's disease
Diamond, S G, Markham, Charles H. , Hoehn, Margaret M., McDowell, Fletcher, Muenter, Manfred D.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 40 | Issue: 5 | Pages: 763-763

10.1212/wnl.40.5.763 | PMID 2330103 Get It